# ABBOTT LABORATORIES (ABT) FY2024 Q3 Balance Sheet

- Company: ABBOTT LABORATORIES (ABT)
- Period: As of 2024-09-30
- Filing: Q3 FY2024 10-Q, filed 2024-10-31, accession number 0001628280-24-044602
- Page: https://plicit.ai/financials/abt/fy2024-q3-balance-sheet
- Chart image: https://plicit.ai/charts/abt-fy2024-q3-balance-sheet-sankey.png

## Chart details

Balance sheet as of 2024-09-30. The chart shows assets, liabilities and equity at that date.

- **Assets**: 74,356,000,000 US dollars
- **Current assets**: 23,802,000,000 US dollars
- **Non-current assets**: 50,554,000,000 US dollars
- **Liabilities (calculated)**: 34,328,000,000 US dollars
- **Current liabilities**: 14,902,000,000 US dollars
- **Non-current liabilities**: 19,426,000,000 US dollars
- **Equity**: 40,028,000,000 US dollars
- **Noncontrolling interest**: 232,000,000 US dollars. Included in consolidated equity; this amount is not added again.
- **Property and equipment, at cost**: 22,857,000,000 US dollars. Part of Net property and equipment, drawn as one net amount.
- **Less: accumulated depreciation and amortization**: negative 12,236,000,000 US dollars. Part of Net property and equipment, drawn as one net amount.
- **Cash and cash equivalents**: 7,558,000,000 US dollars
- **Trade receivables, less allowances of $456 in 2024 and $444 in 2023**: 7,051,000,000 US dollars
- **Finished products**: 4,173,000,000 US dollars
- **Prepaid expenses and other receivables**: 2,150,000,000 US dollars
- **Materials**: 1,763,000,000 US dollars
- **Work in process**: 877,000,000 US dollars
- **Short-term investments**: 230,000,000 US dollars
- **Goodwill**: 23,658,000,000 US dollars
- **Net property and equipment**: 10,621,000,000 US dollars
- **Deferred income taxes and other assets**: 8,011,000,000 US dollars
- **Intangible assets, net of amortization**: 7,352,000,000 US dollars
- **Investments**: 912,000,000 US dollars
- **Other accrued liabilities**: 5,427,000,000 US dollars
- **Trade accounts payable**: 4,034,000,000 US dollars
- **Current portion of long-term debt**: 2,154,000,000 US dollars
- **Salaries, wages and commissions**: 1,618,000,000 US dollars
- **Dividends payable**: 956,000,000 US dollars
- **Income taxes payable**: 713,000,000 US dollars
- **Long-term debt**: 12,825,000,000 US dollars
- **Post-employment obligations, deferred income taxes and other long-term liabilities**: 6,601,000,000 US dollars
- **Earnings employed in the business**: 39,056,000,000 US dollars
- **Common shares, without par value Authorized — 2,400,000,000 shares Issued at stated capital amount — Shares: 2024: 1,991,051,414; 2023: 1,987,883,852**: 25,020,000,000 US dollars
- **Preferred shares, one dollar par value Authorized — 1,000,000 shares, none issued**: 0 US dollars
- **Noncontrolling Interests in Subsidiaries**: 232,000,000 US dollars
- **Common shares held in treasury, at cost — Shares: 2024: 256,595,476; 2023: 253,807,494**: negative 16,476,000,000 US dollars
- **Accumulated other comprehensive income (loss)**: negative 7,804,000,000 US dollars
- **Gross equity (calculated)**: 64,308,000,000 US dollars. Net equity plus the magnitudes of its negative contributions equals gross positive equity. The negative contributions enter this reconciliation as add-backs; their filed signs stay negative.

### Chart connections

- Assets equal liabilities plus consolidated equity. Consolidated equity includes noncontrolling interests when reported.
- Treasury shares and other negative equity contributions reduce equity.